SynthesisJournal of patient safety2026
Incidence of and Risk Factors for Repeat Adverse Drug Events: A Systematic Review.
Synthesis in Journal of patient safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse drug events (ADEs) are unintended harm resulting from appropriate or inappropriate medication use. Many ADE-related emergency department visits are repeat events that occur after re-exposure to a medication that previously caused harm. Identifying risks and risk factors for repeat ADEs could inform clinical decision-making. We conducted a systematic review of literature on repeat ADEs published over a 20-year period. We applied a predefined search strategy in MEDLINE, Embase, and Scopus and extracted data on risk factors (e.g., age, sex, drug type, re-exposure type) and ADE outcomes. We conducted a meta-analysis if 2 or more studies reported on the same drug class, re-exposure type, ADE outcome, and follow-up period. We screened 13,452 articles and included 55. Most studies reported on re-exposures to the same drug (n=44), with few reporting on exposures to new drugs (n=5). The most studied drug classes were antineoplastics (n=20), anticoagulants (n=10), and antibiotics (n=5). The proportion of Repeat ADEs varied widely across studies from <1 to 88%. We were only able to pool data from studies on re-exposure to anticoagulants and found that 10% (95% confidence interval: 4%-19%) rebled within 90 days. Repeat ADE risks varied by drug class, reflecting different patient populations, medications and indicating conditions. Inconsistent reporting prevented quantification of risk factors. Pooled repeat ADE incidence, where available, can inform shared decision-making by providing estimates of ADE risk in the context of re-exposures to treat underlying conditions. Repeat ADEs remain an understudied area, highlighting the need for further research given their clinical significance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.